Outcomes in men with large prostates (≥ 60 cm³) treated with definitive proton therapy for prostate cancer

References

• Harsolia A, Vargas C, Yan D, Brabbins D, Lockman D, Liang J, . Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study. Int J Radiat Oncol Biol Phys 2007;69:1100–9.
   PubMed Web of Science ®Google Scholar
• Pal RP, Bhatt JR, Khan MA, Duggleby S, Camilleri P, Bell CR, . Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy. Brachytherapy 2011;10:107–16.
   PubMed Web of Science ®Google Scholar
• Levinson AW, Ward NT, Sulman A, Mettee LZ, Link RE, Su LM, . The impact of prostate size on perioperative outcomes in a large laparoscopic radical prostatectomy series. J Endourol 2009;23:147–52.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, . Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 1998;16:3380–5.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Harrison A.Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 1997;49:38–45.
   PubMed Web of Science ®Google Scholar
• Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250–61.
   PubMed Web of Science ®Google Scholar
• Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV.Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866–73.
   PubMed Web of Science ®Google Scholar
• Vargas C, Fryer A, Mahajan C, Indelicato D, Horne D, Chellini A, . Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:744–51.
   PubMed Web of Science ®Google Scholar
• Mendenhall NP, Li Z, Hoppe BS, Marcus RB, Jr., Mendenhall WM, Nichols RC, . Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:213–21.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute: Cancer Therapy Evaluation Program; 2006 [updated March 4, 2007]; Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
   Google Scholar
• Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, Shipley WU, Sokol GH, . Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965–74.
   PubMed Web of Science ®Google Scholar
• Aizer AA, Anderson NS, Oh SC, Yu JB, McKeon AM, Decker RH, . The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011;79:379–84.
   PubMed Web of Science ®Google Scholar
• Monroe AT, Faricy PO, Jennings SB, Biggers RD, Gibbs GL, Peddada AV.High-dose-rate brachytherapy for large prostate volumes (> or = 50cc) – Uncompromised dosimetric coverage and acceptable toxicity. Brachytherapy 2008;7:7–11.
   PubMed Web of Science ®Google Scholar
• Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, . Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83–9.
   PubMed Web of Science ®Google Scholar
• Forman JD, Keole S, Bolton S, Tekyi-Mensah S.Association of prostate size with urinary morbidity following mixed conformal neutron and photon irradiation. Int J Radiat Oncol Biol Phys 1999;45:871–5.
   PubMed Web of Science ®Google Scholar
• Sandhu AS, Zelefsky MJ, Lee HJ, Lombardi D, Fuks Z, Leibel SA.Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection. Int J Radiat Oncol Biol Phys 2000;48:643–7.
   PubMed Web of Science ®Google Scholar
• Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R.Sex or survival: Trade-offs between quality and quantity of life. J Clin Oncol 1991;9:328–34.
   PubMed Web of Science ®Google Scholar
• Dacal K, Sereika SM, Greenspan SL.Quality of life in prostate cancer patients taking androgen deprivation therapy. J Am Geriatr Soc 2006;54:85–90.
   PubMed Web of Science ®Google Scholar
• Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, . Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol 2009;55:62–75.
   PubMed Web of Science ®Google Scholar
• Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS.Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy. Prostate Cancer Prostatic Dis 2012;15:237–43.
   PubMed Web of Science ®Google Scholar